{"classes":[{"categories":[{"measurements":[{"comment":"Full range is not applicable due to single participant, and the median value presented here is the actual t1/2 for this single participant.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"3.68"},{"comment":"Full range is not applicable due to single participant, and the median value presented here is the actual t1/2 for this single participant.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"5.64"},{"comment":"Full range is not applicable due to single participant, and the median value presented here is the actual t1/2 for this single participant.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"4.70"},{"groupId":"OG003","lowerLimit":"2.9","upperLimit":"6.4","value":"4.15"},{"comment":"Full range is not applicable due to single participant, and the median value presented here is the actual t1/2 for this single participant.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"4.39"},{"groupId":"OG005","lowerLimit":"3.2","upperLimit":"5.8","value":"4.39"},{"groupId":"OG006","lowerLimit":"3.4","upperLimit":"7.8","value":"6.48"},{"groupId":"OG007","lowerLimit":"3.0","upperLimit":"5.3","value":"3.51"},{"groupId":"OG008","lowerLimit":"1.7","upperLimit":"2.3","value":"1.96"},{"groupId":"OG009","lowerLimit":"3.1","upperLimit":"5.3","value":"3.97"},{"comment":"Full range is not applicable due to single participant, and the median value presented here is the actual t1/2 for this single participant.","groupId":"OG010","lowerLimit":"NA","upperLimit":"NA","value":"2.54"},{"groupId":"OG011","lowerLimit":"2.4","upperLimit":"5.9","value":"4.98"},{"groupId":"OG012","lowerLimit":"2.2","upperLimit":"3.7","value":"3.22"},{"groupId":"OG013","lowerLimit":"3.2","upperLimit":"8.6","value":"5.51"},{"groupId":"OG014","lowerLimit":"3.8","upperLimit":"4.4","value":"4.09"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"11"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"6"},{"groupId":"OG010","value":"1"},{"groupId":"OG011","value":"6"},{"groupId":"OG012","value":"4"},{"groupId":"OG013","value":"11"},{"groupId":"OG014","value":"2"}],"units":"Participants"}],"description":"Plasma samples for PK analysis of GSK525762 were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis.","dispersionType":"Full Range","groups":[{"description":"Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.","id":"OG000","title":"Part 1: GSK525762 5 mg QD"},{"description":"Participants were administered once daily oral dose of 10 mg GSK525762.","id":"OG001","title":"Part 1: GSK525762 10 mg QD"},{"description":"Participants were administered once daily oral dose of 20 mg GSK525762.","id":"OG002","title":"Part 1: GSK525762 20 mg QD"},{"description":"Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.","id":"OG003","title":"Part 1: GSK525762 30 mg QD MM"},{"description":"Participants were administered once daily oral dose of 40 mg GSK525762.","id":"OG004","title":"Part 1: GSK525762 40 mg QD"},{"description":"Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.","id":"OG005","title":"Part 1: GSK525762 40 mg QD MM"},{"description":"Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.","id":"OG006","title":"Part 1: GSK525762 60 mg QD AML"},{"description":"Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.","id":"OG007","title":"Part 1: GSK525762 60 mg QD NHL"},{"description":"Participants with MM were administered once daily oral dose of 60 mg GSK525762.","id":"OG008","title":"Part 1: GSK525762 60 mg QD MM"},{"description":"Participants with AML were administered once daily oral dose of 75 mg GSK525762.","id":"OG009","title":"Part 1: GSK525762 75 mg QD AML"},{"description":"Participants were administered once daily oral dose of 80 mg GSK525762.","id":"OG010","title":"Part 1: GSK525762 80 mg QD"},{"description":"Participants with AML were administered once daily oral dose of 80 mg GSK525762.","id":"OG011","title":"Part 1: GSK525762 80 mg QD AML"},{"description":"Participants with NHL were administered once daily oral dose of 80 mg GSK525762.","id":"OG012","title":"Part 1: GSK525762 80 mg QD NHL"},{"description":"Participants with AML were administered once daily oral dose of 100 mg GSK525762.","id":"OG013","title":"Part 1: GSK525762 100 mg QD AML"},{"description":"Participants with AML were administered once daily oral dose of 120 mg GSK525762.","id":"OG014","title":"Part 1: GSK525762 120 mg QD AML"}],"paramType":"MEDIAN","populationDescription":"PK Population. Only those participants with data available at the specified data points were analyzed.","reportingStatus":"POSTED","timeFrame":"Week 2 Day 7: Pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose","title":"Part 1: T1/2 of GSK525762 Following Repeat Dose Administration","type":"SECONDARY","unitOfMeasure":"Hour"}